Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis
about
International Union of Pharmacology LVIII: update on the P2Y G protein-coupled nucleotide receptors: from molecular mechanisms and pathophysiology to therapyThe RGS protein inhibitor CCG-4986 is a covalent modifier of the RGS4 Galpha-interaction faceCurrent status of high on-treatment platelet reactivity in patients with coronary or peripheral arterial disease: Mechanisms, evaluation and clinical implicationsType 2 Diabetes and ADP Receptor Blocker TherapyP2Y(12) receptors in platelets and other hematopoietic and non-hematopoietic cellsPolymorphic cytochrome P450 enzymes (CYPs) and their role in personalized therapyNormalization of platelet reactivity in clopidogrel-treated subjectsClopidogrel, a P2Y12 receptor antagonist, potentiates the inflammatory response in a rat model of peptidoglycan polysaccharide-induced arthritisMRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in miceThe GPIIb/IIIa (integrin alphaIIbbeta3) odyssey: a technology-driven saga of a receptor with twists, turns, and even a bend.Endobrevin/VAMP-8-dependent dense granule release mediates thrombus formation in vivoIntegrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent.Ticlopidine in its prodrug form is a selective inhibitor of human NTPDase1Leukotrienes and airway inflammationCharacterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.P2Y receptors in the mammalian nervous system: pharmacology, ligands and therapeutic potential.Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesNew highly active antiplatelet agents with dual specificity for platelet P2Y1 and P2Y12 adenosine diphosphate receptorsComparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial.Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.Platelets influence vascularized organ transplants from start to finishMonitoring oral antiplatelet therapy: is it justified?CYP2C19*2/ABCB1-C3435T polymorphism and risk of cardiovascular events in coronary artery disease patients on clopidogrel: is clinical testing helpful?Antiplatelet drugs and the perioperative period: What every urologist needs to knowAntiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions.Update on oral antiplatelet therapy: principles, problems and promises.Cangrelor: a novel P2Y12 receptor antagonist.P2Y12 receptor in platelet activation.Role of antiplatelet therapy in secondary prevention of acute coronary syndrome.Recent advances in the pharmacogenetics of clopidogrel.Safety profile and bleeding risk of ticagrelor compared with clopidogrel.The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.CYP-mediated pharmacologic interference with optimal platelet inhibition.Physiological roles and potential therapeutic applications of the P2X7 receptor in inflammation and pain.Updates in antiplatelet agents used in cardiovascular diseases.Contemporary antiplatelet therapy in patients undergoing percutaneous coronary intervention.Front-loading with clopidogrel plus aspirin followed by dual antiplatelet therapy in the prevention of early stroke recurrence.Efficacy of clopidogrel treatment and platelet responsiveness in peripheral arterial procedures.P2 receptors and platelet function.Prasugrel for Japanese patients with acute coronary syndrome in short-term clinical practice (PRASFIT-Practice I): a postmarketing observational study.
P2860
Q24629255-EF52FE8C-D137-4DCB-AE17-17CA3D2E9A30Q24673940-91CDA11B-6F96-4715-AE3A-E42662323C8DQ26771106-D902F081-5FFE-4B0C-B040-16180A099AD9Q26772996-1691C31E-FA08-4F3E-88AC-6E25BDBE3E47Q26861200-CE35A951-EBF1-4755-B5D2-AD3C95DEED58Q27022665-A0DFE789-6EE1-493B-8263-36ADB99E50F5Q28217935-8607D1AA-44D6-46B7-899A-95E3A3D62722Q28477535-329B7C91-5639-454C-8439-DCA1A0D5553CQ33225547-ECB676BA-E6F6-4F73-B34C-9504562F80FFQ33381441-2C397B50-C83D-4D92-B51E-616DEAFA7AD9Q33435199-5D0E274F-0D4F-42DB-BED6-44563F4E7F29Q33561577-C131CF2A-E122-4A0D-85A1-ADA2B0052549Q34087391-D17ECEFA-937F-4864-BA0D-5A0B7E800CFEQ35106124-72567D19-2AF9-4DA8-8465-AB0E540ADFCBQ35130686-A97A47E9-BA35-46DE-8860-C5D5B18B7BB3Q35163180-D5841E32-C38B-4C9B-B725-D86FA45F13F0Q35752619-EA4F755C-2A7E-4420-871C-DA86AA1D8285Q36359617-ADB96DFE-CCD8-4E15-93A9-33B23AEAD5B4Q36688145-FD0A9103-7BEB-449B-A690-9C5F1D7EF3C9Q37259929-5D0A32CE-EE50-413C-A4F3-2E6A74A31EF7Q37344903-3443521D-F470-436D-8135-F69D9DFF29A6Q37362783-F909B993-45C4-40DE-B3FE-52F84A84B2CDQ37387416-21CA676B-3E43-423F-8FD7-3803FA153093Q37427253-FFF83AAF-B1BD-4D18-857C-676ECFF52A17Q37428365-F5EC2689-E128-4294-8BE6-A9DECD55FE7BQ37486605-3A4DD7A7-AE57-4B96-9ED2-9F03738AD086Q37551923-3B9DF5A1-B617-4365-A42F-82419B95B8AEQ37828158-B91B7644-E72C-4992-85F3-EC4175A94C7BQ37953259-390CCF5A-6449-4FF3-BB71-752D2EA060F9Q37972231-35BBDF95-E650-4EBA-85F7-596FA783CEB9Q38040816-7195AAAE-4EE0-4744-B4BD-A5A051FEBEEEQ38053481-49D600B4-9175-4366-B565-55B88CC278F8Q38073672-B670D9DA-5127-41BF-9332-AC252EBF7915Q38135247-F7E40218-60E0-4875-874F-4AD38A59D581Q38161394-C75A5D6A-53BF-450B-AA19-B4BB2A45A2ACQ38197732-3DDBD00E-7AC3-4C2B-A3A2-06BC6A89165EQ38216499-026E01A8-FE4F-4EE7-889F-4ACA710B9AA5Q38243854-7D381E99-6A8E-4DDA-B81C-D2BDA2D0764EQ38306634-B8CFCD7A-E33D-41BA-AFCF-566870F6802AQ38380609-F9AA7317-B886-4907-B4BB-03B2D3AED489
P2860
Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Clopidogrel and ticlopidine: P ...... prevention of atherothrombosis
@ast
Clopidogrel and ticlopidine: P ...... prevention of atherothrombosis
@en
Clopidogrel and ticlopidine: P ...... prevention of atherothrombosis
@nl
type
label
Clopidogrel and ticlopidine: P ...... prevention of atherothrombosis
@ast
Clopidogrel and ticlopidine: P ...... prevention of atherothrombosis
@en
Clopidogrel and ticlopidine: P ...... prevention of atherothrombosis
@nl
prefLabel
Clopidogrel and ticlopidine: P ...... prevention of atherothrombosis
@ast
Clopidogrel and ticlopidine: P ...... prevention of atherothrombosis
@en
Clopidogrel and ticlopidine: P ...... prevention of atherothrombosis
@nl
P356
P1476
Clopidogrel and ticlopidine: P ...... prevention of atherothrombosis
@en
P2093
Jean-Marc Herbert
Pierre Savi
P304
P356
10.1055/S-2005-869523
P407
P577
2005-04-01T00:00:00Z